CDMOs

R&D

Saudi pharma’s rise as a global CDMO destination: Investment...

Saudi Arabia is steadily establishing itself as a competitive worldwide destination for contract development and manufacturing.

News

Oxford BioMedica confirms private equity takeover talks

Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible takeover.

R&D

pharmaphorum podcast Episode 224, Sigma Mostafa, KBI Biopharma

CDMOs: Their crucial role and how to select one, with Sigma ...

Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.

R&D

Seamless scale-up: Integrated manufacturing becomes the biop...

Today, the demand for speed, quality, and scalability is pushing the industry towards a different model: integrated manufacturing.

News

J&J earmarks $2bn for facility in North Carolina

Johnson & Johnson has filled in some of the detail in its $55 billion investment in US facilities announced earlier this year.

R&D

The sparkling opportunity of precision medicine represented by glittering DNA strand

Built for one: The case for custom formulation in the era of...

The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for diffe